ENCell Co., Ltd. (KOSDAQ:456070)
11,920
-80 (-0.67%)
Oct 10, 2025, 3:30 PM KST
ENCell Revenue
ENCell had revenue of 1.18B KRW in the quarter ending June 30, 2025, a decrease of -36.65%. This brings the company's revenue in the last twelve months to 5.83B, down -49.27% year-over-year. In the year 2024, ENCell had annual revenue of 7.21B, down -31.51%.
Revenue (ttm)
5.83B
Revenue Growth
-49.27%
P/S Ratio
22.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
129.95B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.21B | -3.32B | -31.51% |
Dec 31, 2023 | 10.53B | 3.16B | 42.87% |
Dec 31, 2022 | 7.37B | 3.46B | 88.49% |
Dec 31, 2021 | 3.91B | 2.50B | 178.37% |
Dec 31, 2020 | 1.40B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
LigaChem Biosciences | 148.28B |